molecularbas
treatment
option
cancer
patient
histor
consist
antimetabolit
topoisomeras
poison
tubulin
stabil
recent
protein
kinas
inhibitor
sever
addit
class
undergo
clinic
evalu
eg
hdac
inhibitor
phosphatas
inhibitor
parp
inhibitor
era
molecular
oncolog
drug
began
fda
approv
chronic
myelogen
leukemia
inhibitor
protein
kinas
bcrabl
shortli
thereaft
protein
kinas
inhibitor
eg
variou
malign
kinas
inhibitor
first
new
class
antitumor
agent
target
effector
develop
deliv
efficaci
accompani
reduc
number
sever
side
effect
compar
tradit
toxic
chemotherapeut
agent
attract
therapeut
strategi
resid
exist
multitud
kinas
identifi
function
critic
cell
growth
suggest
select
pharmacolog
action
possibl
new
molecular
target
drug
impact
variou
signal
pathway
posttransl
modificationaddit
kinas
remov
phosphatas
phosphat
group
serin
threonin
tyrosin
target
protein
result
often
activ
deactiv
enzym
parallel
complex
post
translat
modif
strategi
afford
ubiquitinproteasom
pathway
acid
protein
tag
ubiquitin
conjug
sequenti
action
activ
enzym
conjug
enzym
ligas
deconjug
group
lysin
specif
target
protein
consequ
ubiquitylationdeubiquityl
includ
chang
cellular
halflif
thu
activ
target
protein
cellular
compartment
traffick
cytosol
nucleu
cell
membran
vesicl
contain
proteas
case
kinasesphosphatas
select
action
possibl
owe
larg
number
ligas
sever
hundr
dub
approxim
eighti
howev
contrast
phosphoryl
ubiquitin
pathway
includ
addit
level
complex
firstli
singl
ubiquitin
may
conjug
target
protein
ubiquitin
alreadi
conjug
protein
result
polyubiquitin
chain
moreov
polyubiquitin
chain
linkag
may
linear
branch
may
involv
one
sever
lysin
contain
ubiquitin
molecul
eg
consequ
potenti
select
bind
ubiquitin
pathway
enzym
andor
enzym
inhibitor
ubiquityl
target
protein
must
consid
set
ubiquitinproteasom
pathway
offer
third
target
classth
proteasom
receiv
polyubiquityl
protein
degrad
util
variou
proteolyt
activ
past
two
decad
three
molecular
target
class
two
rel
select
one
nonselect
studi
exploit
anticanc
drug
develop
fact
global
target
proteasom
targetselect
dub
ligas
produc
first
posit
drug
discoveri
result
first
efficaci
ubiquitin
pathway
drug
cancer
treatment
bortezomib
follow
meant
comprehens
account
current
state
ubiquitin
pathwaybas
drug
develop
rather
impressionist
view
field
necessari
citat
focus
cancer
though
ubiquitin
relev
cell
process
thu
patholog
consid
order
proteasom
enzym
sequenc
deubiquityl
reaction
potenti
actual
sourc
new
ubiquitin
drug
simpl
consequ
block
cellular
protein
degrad
proteasom
accumul
ubiquityl
protein
sort
appear
upon
first
consider
intoler
consequ
cell
proteasom
thought
cell
garbag
dispos
unit
blockad
assum
result
huge
excess
unwant
proteinsa
toxic
event
contrari
howev
global
respons
har
provid
antitumor
activ
multipl
myeloma
mantl
cell
lymphoma
patient
accompani
manag
toxic
bortezomib
dipeptidylboron
acid
bind
revers
subunit
degrad
chamber
proteasom
therebi
inhibit
approv
fda
treatment
relaps
refractori
multipl
melanoma
follow
impress
activ
clinic
trial
subsequ
bortezomib
approv
first
line
treatment
multipl
myeloma
treatment
relaps
mantl
cell
lymphoma
compound
studi
extens
preclin
clinic
develop
elucid
mechan
cytotox
prefer
tumor
vs
normal
cell
review
bortezomib
clinic
success
mechan
studi
drug
proteasom
inhibitor
receiv
less
attent
clinic
studi
bortezomib
activ
numer
combin
may
expand
clinic
util
nevertheless
detail
mechan
emerg
expect
numer
protein
respons
apoptosi
eg
found
degrad
proteasom
clear
inhibit
proteasom
activ
lead
apoptosi
spare
protein
proteasom
inhibitor
may
also
induc
apoptosi
indirectli
inhibit
activ
therebi
prevent
transcript
variou
antiapoptot
protein
addit
cellular
mechan
studi
suggest
bortezomib
inhibit
angiogenesi
could
contribut
antitumor
activ
efficaci
variou
combin
therapi
overcom
resist
tradit
cytotox
therapi
thu
although
bortezomib
reason
therapeut
index
pleiotrop
cytotox
drug
produc
peripher
neuropathi
toxic
commonli
associ
chemotherapeut
agent
therapeut
window
narrow
doselimit
toxic
evid
treatment
dose
moreov
due
part
tabl
proteasom
inhibitor
current
clinic
develop
approv
fda
mutat
chymotrypsinlik
catalyt
subunit
proteasom
resist
bortezomib
becom
evid
revers
inhibitor
like
bortezomib
offer
potenti
advantag
oral
administr
may
improv
patient
experi
even
though
may
superior
bortezomib
therapeut
index
suscept
resist
howev
lattergener
proteasom
inhibitor
clinic
trial
tabl
may
improv
therapeut
index
part
due
differ
mode
bind
diminish
tendenc
compromis
resist
compar
bortezomib
address
clinic
challeng
two
proteasomerel
strategi
emerg
first
strategi
address
bind
mode
exampl
carfilzomib
next
inhibitor
schedul
fda
review
irrevers
binder
chymotrypsinlik
site
contrast
bortezomib
bind
revers
epoxyketonecarfilzomib
potent
inhibitor
bortezomib
contribut
improv
therapeut
index
second
strategi
exploit
proteasom
heterogen
addit
classic
constitut
proteasom
present
cell
cell
contain
second
proteasom
differ
constitut
proteasom
catalyt
subunit
denot
immunoproteasom
contain
regulatori
particl
second
proteasom
type
induc
interferon
gener
antigen
peptid
immun
respons
known
immunoproteasom
heterogen
strategi
also
exemplifi
carfilzomib
inhibit
constitut
proteasom
immunoproteasom
overcom
bortezomib
resist
preclin
model
interest
note
potent
experiment
immunoproteasom
inhibitor
preferenti
target
subunit
immunoproteasom
like
carfilzomib
overcom
resist
bortezomib
oral
bioavail
truncat
version
carfilzomib
onx
phase
clinic
trial
anoth
potenti
mean
overcom
resist
bortezomib
lie
abil
irrevers
phase
proteasom
inhibitor
contrast
bortezomib
inhibit
trypsinlik
well
chymotrypsinlik
proteas
activ
proteasom
inhibitor
current
preclin
develop
address
issu
therapeut
index
includ
need
activ
broad
spectrum
solid
tumor
resist
variou
way
follow
observ
goldberg
laboratori
suggest
alloster
interact
among
proteasom
subunit
may
offer
addit
therapeut
strategi
kisselev
et
al
develop
inhibitor
select
caspaselik
trypsinlik
subunit
shown
trypsin
siteselect
inhibitor
sensit
myeloma
cell
chymotrypsinlik
site
inhibitor
bortezomib
combin
caspaselik
site
inhibitor
inhibit
cell
growth
absenc
chymotrypsinlik
site
inhibitor
studi
identifi
variou
known
small
molecul
eg
chloroquin
potent
substitut
chloroquin
alloster
inhibitor
clinic
potenti
review
tabl
anticip
alloster
proteasom
inhibitor
similar
enter
clinic
trial
within
next
year
anoth
class
repres
clioquinol
may
work
bind
metal
essenti
proteasom
final
deubiquityl
activ
resid
regulatori
portion
intact
proteasom
recent
identifi
novel
anticanc
target
use
small
molecul
found
function
screen
compound
select
inhibit
deubiquityl
activ
associ
dub
tabl
experiment
proteasom
inhibitor
result
blockad
proteasom
activ
thu
repres
earli
promis
class
proteasom
inhibitor
altern
strategi
target
proteasom
target
enzym
upstream
proteasom
gener
enzym
consid
attract
target
due
fact
multipl
enzym
modul
ubiquitin
conjug
deconjug
thu
target
enzym
offer
greater
degre
specif
therefor
reduc
potenti
side
effect
discuss
current
statu
small
molecul
therapeut
target
ubiquitin
conjug
deconjug
dub
three
enzym
sequenti
involv
target
protein
ubiquityl
activ
conjug
ligas
enzym
current
activ
target
anticanc
drug
discoveri
eight
human
activ
ubiquitin
ubiquitinlik
protein
transfer
conjug
enzym
known
sever
dozen
enzym
sever
hundr
ligas
known
although
clear
mani
potenti
therapeut
relev
nevertheless
data
present
support
argument
select
inhibitor
enzym
found
design
catalys
first
step
conjug
ubiquitin
ubiquitinlik
protein
target
proteinan
atpdepend
coval
attach
ubiquitin
ubiquitinlik
protein
molecul
activ
site
cystein
adenosin
sulfam
analogu
inhibit
enzym
respons
neddyl
coval
addit
ubiquitinlik
protein
specif
target
protein
includ
scf
ligas
link
cell
cycl
regul
case
neddyl
result
progrowth
activ
current
phase
ii
clinic
trial
hematolog
cancer
tabl
experiment
inhibitor
also
report
exampl
irrevers
ubiquitin
activ
site
binder
enter
cell
possibl
reactiv
clinic
candid
nonetheless
use
tool
compound
tabl
ubiquitin
activ
transfer
cystein
enzym
interact
ligas
bind
target
protein
transfer
ubiquitin
cystein
target
protein
lysin
recent
small
molecul
select
alloster
site
inhibitor
enzym
name
report
ubiquityl
among
target
protein
inhibit
ubiquityl
degrad
predict
prevent
tumor
cell
cycl
progress
thu
compound
preclin
develop
potenti
anticanc
agent
ligas
respons
determin
target
protein
ubiquityl
concert
approxim
six
hundr
ligas
known
select
inhibit
given
ligas
like
affect
limit
number
cellular
protein
circumst
translat
less
complic
pharmacolog
potenti
limit
side
effect
major
ligas
possess
classic
activ
site
instead
mediat
proteinprotein
interact
charg
protein
substrat
therefor
perhap
surprisingli
advanc
ligasebas
drug
discoveri
strategi
date
develop
antagonist
bind
attempt
find
antagonist
ligas
human
enzym
among
earliest
exercis
seem
perfect
anticanc
target
respons
ubiquityl
tumor
suppressor
proapoptot
protein
prevail
view
even
though
fewer
tumor
possess
function
number
repres
huge
patient
popul
would
benefit
therapi
direct
inhibit
one
mani
molecular
oncolog
strategi
employ
last
year
maxim
presenc
activ
tumor
review
two
ligas
antagonist
current
clinic
trial
cancer
tabl
direct
specif
regul
substrat
sever
compound
inhibit
member
famili
ligas
known
antiapoptot
protein
iap
also
recent
enter
clinic
trial
iap
ubiquityl
protein
essenti
apoptosi
elimin
function
thu
block
apoptosi
analog
smac
natur
occur
protein
bind
iap
trigger
autoubiquityl
subsum
function
restor
apoptot
activ
specul
opinion
piec
publish
nutlin
compound
might
progress
clinic
trial
owe
poor
anim
efficaci
gener
perhap
complex
drug
discoveri
fact
year
later
two
bind
inhibitor
includ
nutlin
seven
iap
antagonist
phase
iii
clinic
trial
suggest
ligas
constitut
viabl
facil
drug
discoveri
area
addit
iap
least
nine
ligas
link
cancer
like
act
oncoprotein
inhibit
apoptosi
promot
cell
cycl
inhibitor
would
potenti
anticanc
drug
although
effort
made
find
inhibitor
ubiquityl
endpoint
search
complic
particip
three
four
enzym
conjug
reaction
date
drug
target
addit
ligas
enter
clinic
although
sever
inhibitor
report
use
tool
compound
tabl
comprehens
list
potenti
ligas
anticanc
target
see
thu
enzym
involv
conjug
ubiquitin
protein
small
molecul
inhibitor
develop
case
enzym
evalu
clinic
treatment
cancer
clinic
progress
bortezomib
rel
rapid
data
date
suggest
may
take
longer
determin
whether
efficaci
drug
come
inhibitor
ubiquitin
conjug
approxim
eighti
known
dub
proteas
hydrolyz
isopeptid
bond
link
ubiquitin
target
protein
case
anoth
ubiquitin
mani
valid
target
cancer
diseas
dub
serv
recycl
ubiquitin
monom
prevent
proteasom
degrad
protein
tag
ubiquitin
trim
ubiquitin
tag
protein
proteasomeassoci
dub
recent
describ
class
anticanc
target
inhibitor
enzym
discuss
proteasom
section
second
functionspar
target
protein
remov
conjug
ubiquitinthat
made
dub
attract
target
cancer
diseas
dub
target
protein
benefici
exampl
tumor
suppressor
dub
activ
would
therapeut
advantag
would
increas
halflif
benefici
protein
case
activ
dub
would
therapeut
use
exampl
wellstudi
dub
would
requir
activ
therapi
difficult
howev
discov
develop
enzym
activ
compar
receptor
agonist
opposit
strategi
wide
pursuedth
use
dub
inhibitor
prevent
spare
deleteri
target
protein
exampl
oncogen
protein
upon
deubiquityl
ensur
degrad
therebi
decreas
cellular
halflif
past
year
tool
compound
andor
preclin
develop
candid
small
molecul
dub
inhibitor
report
compound
identifi
inhibitor
sever
dub
rang
report
select
respect
dub
cystein
proteas
four
exampl
inhibitor
given
stori
chronicl
state
dubbas
anticanc
drug
develop
present
time
tabl
among
earliest
report
dub
inhibitor
cyclopentenon
prostaglandin
induc
apoptosi
also
increas
cellular
content
polyubiquityl
protein
latter
suggest
nonselect
dub
inhibitor
small
molecul
discov
screen
dub
inhibitor
select
dub
cystein
proteas
inhibit
dub
test
moder
potenc
cell
permeant
thu
use
tool
compound
recent
hbx
origin
report
inhibitor
confirm
nonselect
dub
inhibitor
consider
work
perform
seri
dub
inhibitor
one
earliest
describ
dub
therapeut
interest
neurodegen
diseas
cancer
like
pandub
inhibitor
inhibitor
moder
potenc
enter
cell
addit
mani
select
make
valuabl
tool
compound
translat
research
cancer
neurodegen
diseas
classic
exampl
strategi
ablat
oncoprotein
inhibit
dub
protect
ubiquityl
degrad
exemplifi
search
suitabl
inhibitor
one
first
therapeut
relev
dub
describ
arguabl
activ
pursu
dub
target
cancer
drug
discoveri
today
although
like
dub
deconjug
ubiquitin
sever
target
protein
inhibit
promot
degrad
primari
cellular
target
result
net
stabil
activ
sever
seri
small
molecul
inhibitor
includ
hbx
analog
achiev
cellular
proof
concept
anticip
cellular
effect
protein
activ
compound
preclin
develop
compound
enter
clinic
trial
inhibitor
develop
nonetheless
use
tool
compound
dub
inhibitor
studi
restrict
mammalian
enzym
exampl
competit
small
molecul
inhibitor
demonstr
inhibit
sar
coronaviru
proteas
isopeptidas
papainlik
proteas
plpro
vitro
cellular
viral
replic
assay
notabl
author
abl
obtain
cocryst
structur
bound
plpro
predict
acceler
preclin
develop
seri
thu
dub
well
defin
activ
site
appear
simpler
biochem
target
ligas
dubbas
anticanc
drug
develop
proceed
facil
ligasebas
develop
judg
compound
clinic
late
preclin
develop
forego
illustr
major
paradox
applic
enorm
complex
ubiquitin
proteasom
pathway
cancer
therapeut
articul
follow
question
ubiquitinbas
therapi
heretofor
readili
achiev
use
nonselect
approach
carpet
bomb
proteasom
inhibitor
employ
select
approach
surgic
strike
highli
select
ligas
dub
inhibitor
trivial
answer
may
biochemistri
certain
malign
proteasom
inhibitor
yet
demonstr
util
broad
rang
tumor
type
make
hypersensit
proteasom
inhibitorinduc
apoptosi
henc
therapeut
window
interest
altern
explan
spare
larg
number
protein
degrad
inhibit
proteasom
ensur
multipl
proapoptot
antisurviv
activ
allow
proceed
block
singl
oncogen
dub
ligas
exquisit
select
inhibitor
limit
effect
owe
circumvent
function
redund
compens
enzym
possibl
inhibitor
limit
rather
absolut
select
dub
ligas
exhibit
improv
efficaci
case
recent
approv
dual
kinas
inhibitor
ongo
work
new
inhibitor
proteasom
ubiquitin
pathway
enzym
help
answer
question
work
perform
accord
uniform
requir
manuscript
submit
biochem
journal
http
wwwicmjeorg
dr
mattern
dr
wu
dr
nicholson
fulltim
employe
progenra
incorpor
